Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial.
about
Interventions for melasmaMelasma updateLow-dose 1064-nm Q-switched Nd:YAG laser for the treatment of melasma.The Efficacy and Safety of 4-n-butylresorcinol 0.1% Cream for the Treatment of Melasma: A Randomized Controlled Split-face Trial.Treatment of melasma with a depigmentation cream determined with colorimetry.Treatment of melasma with topical agents, peels and lasers: an evidence-based review.Melasma: clinical diagnosis and management options.Skin needling to enhance depigmenting serum penetration in the treatment of melasmaAssessment of efficacy, safety, and tolerability of 4-n-butylresorcinol 0.3% cream: an Indian multicentric study on melasmaTyrosol and its analogues inhibit alpha-melanocyte-stimulating hormone induced melanogenesis.Rationale of using hypopigmenting drugs and their clinical application in melasma.Skin-lightening effects of a new face care product in patients with melasma.The hypopigmentary action of KI-063 (a new tyrosinase inhibitor) combined with terrein.Salicylic acid for the treatment of melasma: new acquisitions for monitoring the clinical improvement.Medical Management of Melasma: A Review with Consensus Recommendations by Indian Pigmentary Expert Group.Evidence-based Review, Grade of Recommendation, and Suggested Treatment Recommendations for Melasma.4-n-butylresorcinol enhances proteolytic degradation of tyrosinase in B16F10 melanoma cells.Inflammatory features of melasma lesions in Asian skin.Antimelanogenic activity of a novel adamantyl benzylbenzamide derivative, AP736: a randomized, double-blind, vehicle-controlled comparative clinical trial performed in patients with hyperpigmentation during the summer.
P2860
Q24234094-3348A4C0-E3A4-40C3-A638-809841BB6480Q26852298-AAF531D3-2931-48B4-AA1C-BA82C31AACE5Q33590057-250EAD05-5EEA-47BE-907B-296289CA31F6Q33904659-875C1E6E-D2B7-448A-ACF0-C8BAE8F892D0Q33966437-BEF81A34-C39F-4FE7-82A3-79B47853795CQ34359554-51B60C90-DDA8-4A16-9D99-6D2689865BEDQ35574147-D7563E4E-4B49-41C0-B888-AB2F8F6555E3Q35909904-DEA43798-160A-4BDF-93F1-8F118B1E2FC5Q36498770-E2878BB1-A4BB-4B33-B8EF-B89BB53CC85DQ37420840-EA53074A-9F60-49E0-88F7-D27A0643F8FAQ38282983-5CFFC735-28B7-42CB-B36B-D8A5880812CCQ39832928-7D3B6E29-D125-42CD-9025-9B29620CC4E4Q40011491-681AB8D4-33E6-493D-BC2B-7EF148B66A10Q40100622-102CA71E-2BDE-497B-8FB8-F1560AEF52F9Q47101904-A377A397-DD3F-4F8F-B373-B01DA99D1EB6Q47158180-F742C8E6-E336-49D1-BA22-0A67A87322BDQ51463902-CD03A8A0-9A4C-4EC2-99B8-BD64CBC8E0D3Q53026858-0669D8E2-B9D8-4679-9B77-629C21C6FAAEQ53233303-B9395E07-96F2-42CC-B4D6-05622E5A7547
P2860
Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Evaluation of efficacy and saf ...... a randomized controlled trial.
@en
Evaluation of efficacy and saf ...... a randomized controlled trial.
@nl
type
label
Evaluation of efficacy and saf ...... a randomized controlled trial.
@en
Evaluation of efficacy and saf ...... a randomized controlled trial.
@nl
prefLabel
Evaluation of efficacy and saf ...... a randomized controlled trial.
@en
Evaluation of efficacy and saf ...... a randomized controlled trial.
@nl
P2093
P2860
P1476
Evaluation of efficacy and saf ...... a randomized controlled trial.
@en
P2093
Ortonne JP
Queille-Roussel C
P2860
P304
P356
10.1111/J.1365-2133.2007.07814.X
P407
P577
2007-03-28T00:00:00Z